Login to Your Account



Alexion Offers Early, Mixed Phase III Data For Heart Drug

By Randall Osborne


Wednesday, August 6, 2003
Alexion Pharmaceuticals Inc. narrowly missed its primary endpoint in the preliminary analysis of its Phase III heart surgery drug, pexelizumab, but the company said other indicators are encouraging enough to ask the FDA about filing for approval.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription